The domestic demand for medicinal glass tubes is increasing, and the pharmaceutical glass faucet is accelerating the expansion of production

【Pharmaceutical Network Industry News】In recent years, with the continuous expansion of the pharmaceutical market and the stricter supervision of the industry, the quality and safety of drugs have attracted more and more attention
.
At the same time, the medicinal glass market, which is closely related to the quality and safety of the pharmaceutical industry, has also ushered in a good space
for development.
Data show that in 2019, the market size of China's medicinal glass industry has exceeded 20 billion yuan
.
In the pharmaceutical field, the glass bottles used can be divided into three categories, namely soda-lime glass, low-borosilicate glass and neutral borosilicate glass
.
At present, with the promotion of the "Healthy China 2030" strategy and the consistency evaluation and review and approval system, the quality and safety requirements of China's pharmaceutical packaging are constantly improving, and the demand for medicinal glass bottles is also continuing to expand
.
It is understood that in the face of huge market demand, as well as considerable potential space for upgrading, more and more domestic enterprises are increasing their layout, especially in neutral borosilicate glass
.
Taking Shandong pharmaceutical glass as an example, under the impetus of the policy of "consistency evaluation + related approval + collection", the trend of replacing low borosilicate and soda and calcium with borosilicate injection packaging materials is constantly strengthening, and the sales volume of borosilicate molded bottles in the first half of 2022 is close to 400 million, and it is expected to achieve 800-900 million units throughout the year, achieving double growth
。 It is worth mentioning that in August 2022, Shandong Pharmaceutical Glass also plans to raise 1.
866 billion yuan, of which 1.
196 billion yuan is used for the first-class water-resistant medicinal glass bottle project, which has now entered the stage of excavation of the base tank, and the future production capacity is expected to reach 4 billion; 671 million yuan is used for the annual output of 560 million pre-filled syringe expansion and transformation projects, and a series of installation and acceptance
of imported equipment have been completed in the first half of the year 。 On September 20, Linuo Teglass said in response to investors' questions on the interactive platform that part of the production line of the fund-raising investment project "Neutral Borosilicate Medicinal Glass Expansion Project" has met the production conditions and has been officially put into operation in May, and the
project is being promoted as planned 。 On the evening of March 9, 2021, when Zhengchuan disclosed the 2020 annual report, in the planning of the business work in 2021, it also said that it would focus on seven aspects of work, including comprehensively improving the production capacity of boron, vigorously introducing advanced bottle-making production equipment, improving the production capacity of boron products, and meeting the increase of boron products and the market demand
for vaccines and biological products under consistency evaluation.
In addition, many companies also plan to increase their entry into the field
of neutral medicinal glass.
For example, the "Announcement on Joint Investment in the Construction of Neutral Borosilicate Medicinal Glass Tube Project and Related Party Transaction" issued by Kibing Group in May 2020 shows that the company intends to invest in a neutral borosilicate pharmaceutical glass project with a total investment of about 600 million yuan; Deli shares once said on the interactive platform that the company communicates and explores in the field of related glass materials.
.
.
Of course, in addition to domestic companies, since 2020, international giants have also attached great importance to the domestic market, such as SCHOTT and Corning have successively announced the establishment of factories
in China.
In this regard, industry insiders believe that in the future in the field of medicinal glass, especially neutral borosilicate glass, the competition of domestic and foreign pharmaceutical companies will become increasingly fierce
.
In this context, for pharmaceutical packaging enterprises, it is necessary to continue to innovate, increase investment in research and development, and constantly break through the shortcomings of China's key raw materials and core equipment in order to maintain competitiveness and accelerate the pace
of domestic substitution.
Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.